Philippe Moreau
Centre National de la Recherche Scientifique(FR)Centre National de la Recherche Scientifique(FR)Inserm(FR)Inserm(FR)Hotel Dieu Hospital(CA)Centre Hospitalier Universitaire de Nantes(FR)Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers(FR)Hopitaux Civils de Colmar(FR)Laboratoire de Thermique et Energie de Nantes(FR)Centre d'Investigation Clinique de Nantes(FR)Hôtel-Dieu de Paris(FR)Hôpital Pasteur(FR)Centre Hospitalier Départemental Vendée(FR)Institut National du Cancer(FR)Loudi Central Hospital(CN)Université d'Angers(FR)Nantes Université(FR)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, Cancer Treatment and Pharmacology, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma(2016)2,897 cited
- → Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma(2021)2,301 cited
- → Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group(2015)2,132 cited
- → Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma(2016)1,421 cited
- → Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis(2005)1,406 cited
- → Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma(2014)1,316 cited